These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10850451)

  • 1. p53 transdominance but no gain of function in mouse brain tumor model.
    Hegi ME; Klein MA; Rüedi D; Chène P; Hamou MF; Aguzzi A
    Cancer Res; 2000 Jun; 60(11):3019-24. PubMed ID: 10850451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant.
    Klein MA; Rüedi D; Nozaki M; Dell EW; Diserens AC; Seelentag W; Janzer RC; Aguzzi A; Hegi ME
    Oncogene; 2000 Nov; 19(47):5329-37. PubMed ID: 11103934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.
    Wang Y; Zhang Z; Kastens E; Lubet RA; You M
    Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke.
    De Flora S; Balansky RM; D'Agostini F; Izzotti A; Camoirano A; Bennicelli C; Zhang Z; Wang Y; Lubet RA; You M
    Cancer Res; 2003 Feb; 63(4):793-800. PubMed ID: 12591728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
    Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
    Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gain-of-function mutations in the tumor suppressor gene p53.
    van Oijen MG; Slootweg PJ
    Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of a mutant p53 protein arising in a medulloblastoma from a mouse transgenic for the JC virus early region.
    White MK; Skowronska A; Gordon J; Del Valle L; Deshmane SL; Giordano A; Khalili K
    Anticancer Res; 2006; 26(6B):4079-92. PubMed ID: 17201119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
    Olive KP; Tuveson DA; Ruhe ZC; Yin B; Willis NA; Bronson RT; Crowley D; Jacks T
    Cell; 2004 Dec; 119(6):847-60. PubMed ID: 15607980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p53 gene and its role in human brain tumors.
    Bögler O; Huang HJ; Kleihues P; Cavenee WK
    Glia; 1995 Nov; 15(3):308-27. PubMed ID: 8586466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour p53 mutations exhibit promoter selective dominance over wild type p53.
    Monti P; Campomenosi P; Ciribilli Y; Iannone R; Inga A; Abbondandolo A; Resnick MA; Fronza G
    Oncogene; 2002 Mar; 21(11):1641-8. PubMed ID: 11896595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The differential effects of mutant p53 alleles on advanced murine lung cancer.
    Jackson EL; Olive KP; Tuveson DA; Bronson R; Crowley D; Brown M; Jacks T
    Cancer Res; 2005 Nov; 65(22):10280-8. PubMed ID: 16288016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas.
    Parhar P; Ezer R; Shao Y; Allen JC; Miller DC; Newcomb EW
    Brain Res Mol Brain Res; 2005 Jun; 137(1-2):98-103. PubMed ID: 15950766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice.
    Backlund MG; Trasti SL; Backlund DC; Cressman VL; Godfrey V; Koller BH
    Cancer Res; 2001 Sep; 61(17):6577-82. PubMed ID: 11522657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.
    Adhikari AS; Iwakuma T
    Fukuoka Igaku Zasshi; 2009 Jun; 100(6):217-28. PubMed ID: 19670804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions.
    Inga A; Nahari D; Velasco-Miguel S; Friedberg EC; Resnick MA
    Oncogene; 2002 Aug; 21(37):5704-15. PubMed ID: 12173040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
    Willis A; Jung EJ; Wakefield T; Chen X
    Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.
    Marutani M; Tonoki H; Tada M; Takahashi M; Kashiwazaki H; Hida Y; Hamada J; Asaka M; Moriuchi T
    Cancer Res; 1999 Oct; 59(19):4765-9. PubMed ID: 10519380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
    de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53 levels determine outcome during beta-catenin tumor initiation and metastasis in the mammary gland and male germ cells.
    Ridgeway AG; McMenamin J; Leder P
    Oncogene; 2006 Jun; 25(25):3518-27. PubMed ID: 16434961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.